2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
(2023) In Annals of the Rheumatic Diseases 82(6). p.742-753- Abstract
Objectives: To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Methods: An international Task Force (TF) (22 members/15 countries) formulated recommendations, supported by systematic literature review findings. Level of evidence and grade of recommendation were assigned for each recommendation. Level of agreement was provided anonymously by each TF member. Results: Four overarching principles (OAP) and eight recommendations were developed. The OAPs highlight the need for infections to be discussed with patients and with other medical specialties, in accordance with national regulations. In addition to... (More)
Objectives: To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Methods: An international Task Force (TF) (22 members/15 countries) formulated recommendations, supported by systematic literature review findings. Level of evidence and grade of recommendation were assigned for each recommendation. Level of agreement was provided anonymously by each TF member. Results: Four overarching principles (OAP) and eight recommendations were developed. The OAPs highlight the need for infections to be discussed with patients and with other medical specialties, in accordance with national regulations. In addition to biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for which screening for latent tuberculosis (TB) should be performed, screening could be considered also before conventional synthetic DMARDs, glucocorticoids and immunosuppressants. Interferon gamma release assay should be preferred over tuberculin skin test, where available. Hepatitis B (HBV) antiviral treatment should be guided by HBV status defined prior to starting antirheumatic drugs. All patients positive for hepatitis-C-RNA should be referred for antiviral treatment. Also, patients who are non-immune to varicella zoster virus should be informed about the availability of postexposure prophylaxis should they have contact with this pathogen. Prophylaxis against Pneumocystis jirovecii seems to be beneficial in patients treated with daily doses >15-30 mg of prednisolone or equivalent for >2-4 weeks. Conclusions: These recommendations provide guidance on the screening and prevention of chronic and opportunistic infections. Their adoption in clinical practice is recommended to standardise and optimise care to reduce the burden of opportunistic infections in people living with AIIRD.
(Less)
- author
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Antirheumatic Agents, Autoimmune Diseases, Tuberculosis
- in
- Annals of the Rheumatic Diseases
- volume
- 82
- issue
- 6
- pages
- 742 - 753
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:36328476
- scopus:85142329502
- ISSN
- 0003-4967
- DOI
- 10.1136/ard-2022-223335
- language
- English
- LU publication?
- yes
- id
- 3fc1d5cc-c2e6-445b-ad1f-13d5adc60c16
- date added to LUP
- 2023-02-08 15:14:58
- date last changed
- 2024-04-14 18:47:23
@article{3fc1d5cc-c2e6-445b-ad1f-13d5adc60c16,
abstract = {{<p>Objectives: To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Methods: An international Task Force (TF) (22 members/15 countries) formulated recommendations, supported by systematic literature review findings. Level of evidence and grade of recommendation were assigned for each recommendation. Level of agreement was provided anonymously by each TF member. Results: Four overarching principles (OAP) and eight recommendations were developed. The OAPs highlight the need for infections to be discussed with patients and with other medical specialties, in accordance with national regulations. In addition to biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for which screening for latent tuberculosis (TB) should be performed, screening could be considered also before conventional synthetic DMARDs, glucocorticoids and immunosuppressants. Interferon gamma release assay should be preferred over tuberculin skin test, where available. Hepatitis B (HBV) antiviral treatment should be guided by HBV status defined prior to starting antirheumatic drugs. All patients positive for hepatitis-C-RNA should be referred for antiviral treatment. Also, patients who are non-immune to varicella zoster virus should be informed about the availability of postexposure prophylaxis should they have contact with this pathogen. Prophylaxis against Pneumocystis jirovecii seems to be beneficial in patients treated with daily doses >15-30 mg of prednisolone or equivalent for >2-4 weeks. Conclusions: These recommendations provide guidance on the screening and prevention of chronic and opportunistic infections. Their adoption in clinical practice is recommended to standardise and optimise care to reduce the burden of opportunistic infections in people living with AIIRD.</p>}},
author = {{Fragoulis, George E. and Nikiphorou, Elena and Dey, Mrinalini and Zhao, Sizheng Steven and Courvoisier, Delphine Sophie and Arnaud, Laurent and Atzeni, Fabiola and Behrens, Georg M.N. and Bijlsma, Johannes W.J. and Böhm, Peter and Constantinou, Costas A. and Garcia-Diaz, Silvia and Kapetanovic, Meliha Crnkic and Lauper, Kim and Luís, Mariana and Morel, Jacques and Nagy, György and Poleverino, Eva and Van Rompay, Jef and Sebastiani, Marco and Strangfeld, Anja and De Thurah, Annette and Galloway, James and Hyrich, Kimme L.}},
issn = {{0003-4967}},
keywords = {{Antirheumatic Agents; Autoimmune Diseases; Tuberculosis}},
language = {{eng}},
number = {{6}},
pages = {{742--753}},
publisher = {{BMJ Publishing Group}},
series = {{Annals of the Rheumatic Diseases}},
title = {{2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases}},
url = {{http://dx.doi.org/10.1136/ard-2022-223335}},
doi = {{10.1136/ard-2022-223335}},
volume = {{82}},
year = {{2023}},
}